Qiang Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Qiang Sun has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Changjun Wang
Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
19 shared publicationsYan Lin
Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
18 shared publicationsFeng Mao
Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
16 shared publicationsYidong Zhou
Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China
16 shared publicationsHanjiang Zhu
Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China
11 shared publicationsXin Huang
Department of Breast Surgery, Peking Union Medical College Hospital
11 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , 5914207
Brain Metastasis of Triple‐Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and is characterized by an early metastatic tendency, marked biological heterogeneity, and poor clinical outcomes. Among all distant metastatic sites, the brain represents one of the most devastating locations, as brain metastasis is associated with substantial neurological morbidity, limited therapeutic options, and short survival. TNBC displays a disproportionate propensity for brain metastasis compared with hormone receptor‐positive disease, yet effective systemic treatment remains challenging because of the blood–brain barrier (BBB), the distinct brain tumor microenvironment (TME), and the absence of broadly applicable molecular targets. In this review, we summarize the molecular basis of TNBC brain metastasis with an emphasis on four major aspects: tumor microenvironmental remodeling, BBB interaction, oncogenic signaling pathways, and metabolic reprogramming. We discuss how reactive astrocytes, microglia, inflammatory cytokines, and tumor‐intrinsic programs collectively facilitate brain colonization and therapeutic resistance. In addition, we review current and emerging treatment strategies, including chemotherapy, antibody–drug conjugates, targeted therapy, immunotherapy, and novel drug‐delivery systems. Particular attention is given to the translational gap between preclinical promise and clinical benefit, the frequent exclusion of patients with active brain metastases from clinical trials, and the need for more rigorous intracranial efficacy assessment. A better understanding of the dynamic interaction between TNBC cells and the brain niche may support the development of more effective and biologically informed therapeutic strategies for this high‐risk population.
- 1 January 2026
- Published by Wiley in The Breast Journal
- Vol. 2026 (1) , 5914207
Open AccessBrain Metastasis of Triple‐Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies
Triple‐negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and is characterized by an early metastatic tendency, marked biological heterogeneity, and poor clinical outcomes. Among all distant metastatic sites, the brain represents one of the most devastating locations, as brain metastasis is associated with substantial neurological morbidity, limited therapeutic options, and short survival. TNBC displays a disproportionate propensity for brain metastasis compared with hormone receptor‐positive disease, yet effective systemic treatment remains challenging because of the blood–brain barrier (BBB), the distinct brain tumor microenvironment (TME), and the absence of broadly applicable molecular targets. In this review, we summarize the molecular basis of TNBC brain metastasis with an emphasis on four major aspects: tumor microenvironmental remodeling, BBB interaction, oncogenic signaling pathways, and metabolic reprogramming. We discuss how reactive astrocytes, microglia, inflammatory cytokines, and tumor‐intrinsic programs collectively facilitate brain colonization and therapeutic resistance. In addition, we review current and emerging treatment strategies, including chemotherapy, antibody–drug conjugates, targeted therapy, immunotherapy, and novel drug‐delivery systems. Particular attention is given to the translational gap between preclinical promise and clinical benefit, the frequent exclusion of patients with active brain metastases from clinical trials, and the need for more rigorous intracranial efficacy assessment. A better understanding of the dynamic interaction between TNBC cells and the brain niche may support the development of more effective and biologically informed therapeutic strategies for this high‐risk population.
- Open Access
- 26 November 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Pre-residency research productivity and its impact on admission to top-tier U.S. residency programs: a meta-analysis across specialties in surgical education
Pre-residency research productivity is widely regarded as a critical factor for medical students aspiring to competitive residency programs. However, its s
- 26 November 2025
- Published by Springer Nature in BMC Medical Education
- Vol. 26 (1)
Open AccessPre-residency research productivity and its impact on admission to top-tier U.S. residency programs: a meta-analysis across specialties in surgical education
Pre-residency research productivity is widely regarded as a critical factor for medical students aspiring to competitive residency programs. However, its s
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (10) , 1858-1872
Prognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study
Original Article Prognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study Jialin Zhao, Xing Chen, Zijuan Zhang, Dachun Zhao, Xi Cao, Feng Mao, Qiang Sun, Li Peng
- 1 October 2025
- Published by AME Publishing Company in Gland Surgery
- Vol. 14 (10) , 1858-1872
Open AccessPrognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study
Original Article Prognostic value of the systemic immune-inflammation index in recurrent/metastatic triple-negative breast cancer: a retrospective cohort study Jialin Zhao, Xing Chen, Zijuan Zhang, Dachun Zhao, Xi Cao, Feng Mao, Qiang Sun, Li Peng
- Open Access
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1433907
Predictive value of methylene blue combined with indocyanine green in sentinel lymph node metastasis in breast cancer: a prospective pilot cohort study
Background: The status of sentinel lymph nodes is crucial for prognosis and treatment decisions in breast cancer patients. This study aimed to evaluate the predictive value of combined methylene blue and indocyanine green for sentinel lymph node metastasis in breast cancer.Methods: This prospective cohort study enrolled 90 clinically node-negative breast cancer patients. Methylene blue and indocyanine green were injected locally before surgery. Sentinel lymph nodes were grouped based on fluorescence intensity and methylene blue staining. A binary logistic regression model was established using 285 lymph node groups to predict metastatic risk.Results: A total of 475 lymph nodes were identified, with 33 being metastatic. The metastatic risk reached 70% for partially blue-stained and weakly fluorescent lymph nodes between 1-2 cm. The model revealed associations between lymph node size, dye staining patterns, and metastatic risks (P<0.05). The AUC of the ROC curve was 0.855.Conclusions: The staining pattern of combined methylene blue and indocyanine green could predict risks of sentinel lymph node metastasis and facilitate rapid intraoperative identification of high-risk lymph nodes.
- 9 October 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1433907
Open AccessPredictive value of methylene blue combined with indocyanine green in sentinel lymph node metastasis in breast cancer: a prospective pilot cohort study
Background: The status of sentinel lymph nodes is crucial for prognosis and treatment decisions in breast cancer patients. This study aimed to evaluate the predictive value of combined methylene blue and indocyanine green for sentinel lymph node metastasis in breast cancer.Methods: This prospective cohort study enrolled 90 clinically node-negative breast cancer patients. Methylene blue and indocyanine green were injected locally before surgery. Sentinel lymph nodes were grouped based on fluorescence intensity and methylene blue staining. A binary logistic regression model was established using 285 lymph node groups to predict metastatic risk.Results: A total of 475 lymph nodes were identified, with 33 being metastatic. The metastatic risk reached 70% for partially blue-stained and weakly fluorescent lymph nodes between 1-2 cm. The model revealed associations between lymph node size, dye staining patterns, and metastatic risks (P<0.05). The AUC of the ROC curve was 0.855.Conclusions: The staining pattern of combined methylene blue and indocyanine green could predict risks of sentinel lymph node metastasis and facilitate rapid intraoperative identification of high-risk lymph nodes.
- Open Access
- 27 August 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial
Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes. Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included for a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea. Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one case of grade ≥3 decreased neutrophil count in each group. Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application. Trial registration ClinicalTrials.gov, NCT04659499
- 27 August 2024
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 13
Open AccessDifferent treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial
Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes. Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included for a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea. Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one case of grade ≥3 decreased neutrophil count in each group. Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application. Trial registration ClinicalTrials.gov, NCT04659499
- Open Access
Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial
Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes. Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included for a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea. Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one case of grade ≥3 decreased neutrophil count in each group. Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application. Trial registration ClinicalTrials.gov, NCT04659499
Open AccessDifferent treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial
Background Pyrotinib, a pan-HER tyrosine kinase inhibitor, demonstrates efficacy in the treatment of HER2-positive breast cancer. However, the frequent occurrence of treatment-emergent diarrhea necessitating discontinuation, impacts patient outcomes. Methods In this multicenter, open-label, phase II PHAEDRA study enrolling early stage HER2-positive patients for postoperative treatment with nab-paclitaxel and pyrotinib, 120 patients were included for a sub-study and randomly divided into two groups to receive 21 days and 42 days of loperamide for primary prophylaxis of diarrhea, followed by as-needed usage. The primary outcome was the incidence of grade ≥3 diarrhea. Results Fifty-eight patients in the 21-day group and 59 patients in the 42-day group received at least one dose of pyrotinib. With a median follow-up of 12.1 months, all patients experienced diarrhea of any grade, with grade ≥3 events in 39.7% of the 21-day group and 42.4% of the 42-day group (relative risk: 0.94; 95% confidence interval: 0.61-1.45). The most common treatment-emergent adverse events, other than diarrhea, were hypoesthesia, vomiting, nausea, and rash, mostly grade 1-2, except for one case of grade ≥3 decreased neutrophil count in each group. Conclusion No significant differences were observed between 21-day and 42-day loperamide durations in preventing grade ≥3 diarrhea. Considering the economic cost and patient compliance, 21-day loperamide prophylaxis might represent a more pragmatic and appropriate approach for clinical application. Trial registration ClinicalTrials.gov, NCT04659499
- Open Access
- 29 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13401
SP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway
The long non-coding RNA (lncRNA) actin fiber-associated protein-1 antisense RNA 1 (AFAP1-AS1) exerted oncogenic activity in triple-negative breast cancer (TNBC). We designed this study and conducted it to investigate the upstream regulation mechanism of AFAP1-AS1 in TNBC tumorigenesis. In this work, we proved the localization of AFAP1-AS1 in the cytoplasm. We elucidated the mechanism by which the transcription factor specificity protein 1 (SP1) modulated AFAP1-AS1 in TNBC progression, which has yet to be thoroughly studied. Dual luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay revealed a strong affinity of SP1 toward the promoter regions P3 of AFAP1-AS1, proving the gene expression regulation of AFAP1-AS1 via SP1 in TNBC. Additionally, SP1 could facilitate the tumorigenesis of TNBC cells in vitro and in vivo by regulating the AFAP1-AS1 expression. Furthermore, silenced AFAP1-AS1 suppressed the expression of genes in the mTOR pathway, such as eukaryotic translation initiation factor 4B (EIF4B), mitogen-activated protein kinase-associated protein 1 (MAPKAP1), SEH1-like nucleoporin (SEH1L), serum/glucocorticoid regulated kinase 1 (SGK1), and its target NEDD4-like E3 ubiquitin protein ligase (NEDD4L), and promoted the gene expression of s-phase kinase-associated protein 2 (SKP2). Overall, this study emphasized the oncogenic role of SP1 and AFAP1-AS1 in TNBC and illustrated the AFAP1-AS1 upstream interaction with SP1 and the downstream modulatory of mTOR signaling, thus offering insights into the tumorigenesis mechanism in TNBC.
- 29 August 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (17) , 13401
Open AccessSP1-Induced Upregulation of LncRNA AFAP1-AS1 Promotes Tumor Progression in Triple-Negative Breast Cancer by Regulating mTOR Pathway
The long non-coding RNA (lncRNA) actin fiber-associated protein-1 antisense RNA 1 (AFAP1-AS1) exerted oncogenic activity in triple-negative breast cancer (TNBC). We designed this study and conducted it to investigate the upstream regulation mechanism of AFAP1-AS1 in TNBC tumorigenesis. In this work, we proved the localization of AFAP1-AS1 in the cytoplasm. We elucidated the mechanism by which the transcription factor specificity protein 1 (SP1) modulated AFAP1-AS1 in TNBC progression, which has yet to be thoroughly studied. Dual luciferase reporter assay and chromatin immunoprecipitation (ChIP) assay revealed a strong affinity of SP1 toward the promoter regions P3 of AFAP1-AS1, proving the gene expression regulation of AFAP1-AS1 via SP1 in TNBC. Additionally, SP1 could facilitate the tumorigenesis of TNBC cells in vitro and in vivo by regulating the AFAP1-AS1 expression. Furthermore, silenced AFAP1-AS1 suppressed the expression of genes in the mTOR pathway, such as eukaryotic translation initiation factor 4B (EIF4B), mitogen-activated protein kinase-associated protein 1 (MAPKAP1), SEH1-like nucleoporin (SEH1L), serum/glucocorticoid regulated kinase 1 (SGK1), and its target NEDD4-like E3 ubiquitin protein ligase (NEDD4L), and promoted the gene expression of s-phase kinase-associated protein 2 (SKP2). Overall, this study emphasized the oncogenic role of SP1 and AFAP1-AS1 in TNBC and illustrated the AFAP1-AS1 upstream interaction with SP1 and the downstream modulatory of mTOR signaling, thus offering insights into the tumorigenesis mechanism in TNBC.
- Open Access
- 21 July 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1207991
Case Report: Exploration of changes in serum immunoinflammation-related protein complexes of patients with metastatic breast cancer
Patients with advanced breast cancer are difficult to treat and have poor prognosis. At present, the commonly used methods to monitor the disease progression of breast cancer are imaging examinations such as breast ultrasound, mammography and peripheral blood tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3). However, none of them can detect tumor progression at an early stage. Serum immunoinflammation-related protein complexes (IIRPCs) showed potential to indicate cancer progression. Therefore, we attempted to monitor the level of IIRPCs in peripheral blood of patients with metastatic breast cancer and compare it with patients’ treatment and disease progression, and here we performed case reports of two of them.
- 21 July 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1207991
Open AccessCase Report: Exploration of changes in serum immunoinflammation-related protein complexes of patients with metastatic breast cancer
Patients with advanced breast cancer are difficult to treat and have poor prognosis. At present, the commonly used methods to monitor the disease progression of breast cancer are imaging examinations such as breast ultrasound, mammography and peripheral blood tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3). However, none of them can detect tumor progression at an early stage. Serum immunoinflammation-related protein complexes (IIRPCs) showed potential to indicate cancer progression. Therefore, we attempted to monitor the level of IIRPCs in peripheral blood of patients with metastatic breast cancer and compare it with patients’ treatment and disease progression, and here we performed case reports of two of them.
- 27 May 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-20
G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression
Glucose-6-phosphate dehydrogenase (G6PD) is involved in triple-negative breast cancer (TNBC) progression. Metabolic crosstalk between cancer cells and tumor-associated macrophages mediates tumor progression in TNBC. Molecular biological methods were applied to clarify the mechanism of the crosstalk between TNBC cells and M2 macrophages. In the present study, we verified that G6PD overexpression drives M2 macrophage polarization by directly combining with phospho-STAT1 and upregulating CCL2 and TGF-β1 secretion in TNBC cells. In turn, M2-like TAMs activated TNBC cells through IL-10 secretion, providing feedback to upregulate G6PD and promote TNBC cell migration and proliferation in vitro. Furthermore, we found that 6-AN (a specific inhibitor of G6PD) not only suppressed the cancer-driven polarization of macrophages toward the M2 phenotype but also inhibited the inherent M2 polarization of macrophages. Targeting the G6PD-regulated pentose phosphate pathway restrained TNBC progression and M2-type polarization of macrophages in vitro and in vivo.
- 27 May 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-20
G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression
Glucose-6-phosphate dehydrogenase (G6PD) is involved in triple-negative breast cancer (TNBC) progression. Metabolic crosstalk between cancer cells and tumor-associated macrophages mediates tumor progression in TNBC. Molecular biological methods were applied to clarify the mechanism of the crosstalk between TNBC cells and M2 macrophages. In the present study, we verified that G6PD overexpression drives M2 macrophage polarization by directly combining with phospho-STAT1 and upregulating CCL2 and TGF-β1 secretion in TNBC cells. In turn, M2-like TAMs activated TNBC cells through IL-10 secretion, providing feedback to upregulate G6PD and promote TNBC cell migration and proliferation in vitro. Furthermore, we found that 6-AN (a specific inhibitor of G6PD) not only suppressed the cancer-driven polarization of macrophages toward the M2 phenotype but also inhibited the inherent M2 polarization of macrophages. Targeting the G6PD-regulated pentose phosphate pathway restrained TNBC progression and M2-type polarization of macrophages in vitro and in vivo.
- Open Access
- 30 June 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 905846
The Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis
Background: The prognostic and clinical value of tumor-associated macrophages (TAMs) in patients with breast cancer (BCa) remains unclear. We conducted the current meta-analysis to systematically evaluate the association of CD68+ and CD163+ TAM density with the prognosis and clinicopathologic features of BCa patients.Methods: Searches of Web of Science, PubMed, and EMBASE databases were performed up to January 31, 2022. The meta-analysis was conducted using hazard risks (HRs) and 95% confidence intervals (CIs) for survival data including overall survival (OS), disease-free survival (DFS), and BCa specific survival. Sensitivity and meta-regression analyses were also conducted to identify the robustness of the pooled estimates.Results: Our literature search identified relevant articles involving a total of 8,496 patients from 32 included studies. Our analysis indicates that a high CD68+ TAM density in the tumor stoma was significantly linked with poor OS (HR 2.46, 95% CI, 1.83–3.31, PP=0.02) compared to low CD68+ TAM density. A significant association was also found in the tumor nest. Analysis of CD163+ TAM density showed similar results (all PPPin vivo experiments are needed to elucidate the underlying mechanism of TAMs.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022304853, identifier CRD42022304853.
- 30 June 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 905846
Open AccessThe Prognostic and Clinical Value of Tumor-Associated Macrophages in Patients With Breast Cancer: A Systematic Review and Meta-Analysis
Background: The prognostic and clinical value of tumor-associated macrophages (TAMs) in patients with breast cancer (BCa) remains unclear. We conducted the current meta-analysis to systematically evaluate the association of CD68+ and CD163+ TAM density with the prognosis and clinicopathologic features of BCa patients.Methods: Searches of Web of Science, PubMed, and EMBASE databases were performed up to January 31, 2022. The meta-analysis was conducted using hazard risks (HRs) and 95% confidence intervals (CIs) for survival data including overall survival (OS), disease-free survival (DFS), and BCa specific survival. Sensitivity and meta-regression analyses were also conducted to identify the robustness of the pooled estimates.Results: Our literature search identified relevant articles involving a total of 8,496 patients from 32 included studies. Our analysis indicates that a high CD68+ TAM density in the tumor stoma was significantly linked with poor OS (HR 2.46, 95% CI, 1.83–3.31, PP=0.02) compared to low CD68+ TAM density. A significant association was also found in the tumor nest. Analysis of CD163+ TAM density showed similar results (all PPPin vivo experiments are needed to elucidate the underlying mechanism of TAMs.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022304853, identifier CRD42022304853.